Literature DB >> 20362975

Need for speed: evaluating slopes of OCD recovery in behavior therapy enhanced with d-cycloserine.

Gregory S Chasson1, Ulrike Buhlmann, David F Tolin, Sowmya R Rao, Hannah E Reese, Theresa Rowley, Kaitlyn S Welsh, Sabine Wilhelm.   

Abstract

Evidence suggests that the antibiotic d-cycloserine (DCS) enhances the treatment effects of exposure and response prevention (ERP) for Obsessive-Compulsive Disorder (OCD). Further, evidence suggests that the effects of DCS diminish partway through treatment, but it is unclear to what extent. In an effort to evaluate these issues, the current study re-analyzes data from a 10-session randomized controlled trial of ERP+DCS versus ERP+placebo in a sample of 22 adults with OCD. We analyzed repeated-measures mixed models with random slopes and intercepts across different intervals: sessions 1-10, 1-5, and 6-10. The results indicate that the course of ERP was 2.3 times faster over the full 10 sessions for the DCS compared to the placebo group, and nearly six times quicker in the first half of ERP. Further interpretation of the results suggests that DCS does not amplify the effects of ERP, but instead initiates treatment effects sooner in treatment. In addition, DCS does not necessarily lose its effect over repeated use, but instead may exhaust its maximum utility after effectively jump-starting ERP. Ultimately, DCS may provide a means for curtailing treatment costs, decreasing treatment dropout and refusal rates, and enhancing access to care. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20362975     DOI: 10.1016/j.brat.2010.03.007

Source DB:  PubMed          Journal:  Behav Res Ther        ISSN: 0005-7967


  33 in total

Review 1.  Enhancement of Psychosocial Treatment With D-Cycloserine: Models, Moderators, and Future Directions.

Authors:  Michael W Otto; M Alexandra Kredlow; Jasper A J Smits; Stefan G Hofmann; David F Tolin; Rianne A de Kleine; Agnes van Minnen; A Eden Evins; Mark H Pollack
Journal:  Biol Psychiatry       Date:  2015-09-25       Impact factor: 13.382

2.  Advances in the treatment of pediatric obsessive-compulsive d-cycloserine with exposure and response prevention.

Authors:  Joseph F McGuire; Adam B Lewin; Daniel A Geller; Ashley Brown; Kesley Ramsey; Jane Mutch; Andrew Mittelman; Jamie Micco; Cary Jordan; Sabine Wilhelm; Tanya K Murphy; Brent J Small; Eric A Storch
Journal:  Neuropsychiatry (London)       Date:  2012-08

3.  Cue exposure and response prevention with heavy smokers: a laboratory-based randomised placebo-controlled trial examining the effects of D-cycloserine on cue reactivity and attentional bias.

Authors:  Sunjeev K Kamboj; Alyssa Joye; Ravi K Das; Andrew J W Gibson; Celia J A Morgan; H Valerie Curran
Journal:  Psychopharmacology (Berl)       Date:  2011-11-22       Impact factor: 4.530

Review 4.  From Pavlov to PTSD: the extinction of conditioned fear in rodents, humans, and anxiety disorders.

Authors:  Michael B VanElzakker; M Kathryn Dahlgren; F Caroline Davis; Stacey Dubois; Lisa M Shin
Journal:  Neurobiol Learn Mem       Date:  2013-12-07       Impact factor: 2.877

5.  Does d-Cycloserine Augmentation of CBT Improve Therapeutic Homework Compliance for Pediatric Obsessive-Compulsive Disorder?

Authors:  Jennifer M Park; Brent J Small; Daniel A Geller; Tanya K Murphy; Adam B Lewin; Eric A Storch
Journal:  J Child Fam Stud       Date:  2014-07-01

6.  D-Cycloserine as an augmentation strategy with cognitive-behavioral therapy for social anxiety disorder.

Authors:  Stefan G Hofmann; Jasper A J Smits; David Rosenfield; Naomi Simon; Michael W Otto; Alicia E Meuret; Luana Marques; Angela Fang; Candyce Tart; Mark H Pollack
Journal:  Am J Psychiatry       Date:  2013-07       Impact factor: 18.112

7.  A high-throughput clinical assay for testing drug facilitation of exposure therapy.

Authors:  Thomas L Rodebaugh; Cheri A Levinson; Eric J Lenze
Journal:  Depress Anxiety       Date:  2013-01-02       Impact factor: 6.505

8.  Efficacy of Augmentation of Cognitive Behavior Therapy With Weight-Adjusted d-Cycloserine vs Placebo in Pediatric Obsessive-Compulsive Disorder: A Randomized Clinical Trial.

Authors:  Eric A Storch; Sabine Wilhelm; Susan Sprich; Aude Henin; Jamie Micco; Brent J Small; Joseph McGuire; P Jane Mutch; Adam B Lewin; Tanya K Murphy; Daniel A Geller
Journal:  JAMA Psychiatry       Date:  2016-08-01       Impact factor: 21.596

Review 9.  Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders.

Authors:  Martin A Katzman; Pierre Bleau; Pierre Blier; Pratap Chokka; Kevin Kjernisted; Michael Van Ameringen; Martin M Antony; Stéphane Bouchard; Alain Brunet; Martine Flament; Sophie Grigoriadis; Sandra Mendlowitz; Kieron O'Connor; Kiran Rabheru; Peggy M A Richter; Melisa Robichaud; John R Walker
Journal:  BMC Psychiatry       Date:  2014-07-02       Impact factor: 3.630

10.  A randomized, double-blind evaluation of D-cycloserine or alprazolam combined with virtual reality exposure therapy for posttraumatic stress disorder in Iraq and Afghanistan War veterans.

Authors:  Barbara Olasov Rothbaum; Matthew Price; Tanja Jovanovic; Seth D Norrholm; Maryrose Gerardi; Boadie Dunlop; Michael Davis; Bekh Bradley; Erica J Duncan; Albert Rizzo; Kerry J Ressler
Journal:  Am J Psychiatry       Date:  2014-06       Impact factor: 18.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.